All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 2nd How to Diagnose & Treat CML / MPN, the MPN Hub spoke to Heinz Gisslinger, Medical University of Vienna, Vienna, AT. We asked, What’s new for the management of polycythemia vera (PV)?
What’s new for the management of polycythemia vera?
Recent years have seen progress in the management of PV in the form of lowering hematocrit levels and using aspirin to prevent thromboembolic events. Gisslinger discusses when and how to use cytoreductive therapy based on available data on ropeginterferon compared with hydroxyurea in PV.
Subscribe to get the best content related to MPN delivered to your inbox